The global erectile dysfunction drugs market was valued at USD 2.30 billion in 2021 and is expected to expand at a compounded annual growth rate (CAGR) of 8.5% from 2022 to 2030. The increasing burden of lifestyle diseases and rising adoption of a sedentary lifestyle are responsible for the increasing incidence of Erectile Dysfunction (ED) worldwide. According to World Health Organization (WHO) report, around 15% of the male population were reported to be affected by erectile dysfunction every year which is projected to reach 320 million by 2025. Hence, increasing disease prevalence and rising demand for ED medicines are among the key factors driving the growth of the market. The COVID-19 pandemic had a positive impact on the sales of erectile dysfunction drugs owing to increased demand for products.
According to the University of Pittsburgh's School of Medicine, there was high growth in sales of erectile dysfunction drugs due to the government-imposed lockdown in 2020. Among all ED drugs, Cialis (Tadalafil) witnessed significant growth in sales in the U.S. Moreover, other factors such as easy access to ED drugs supported the growth of the market for erectile dysfunction drugs. Currently, various drugs are used to manage erectile dysfunction including, sildenafil (Revatio, Viagra), vardenafil (Levitra, Staxyn), tadalafil (Adcirca, Cialis), and avanafil (Stendra) among others.
Depending on the dose, generic sildenafil is frequently offered for a significantly lesser cost than Viagra, which typically costs around USD 70 per pill. Therefore, the availability of affordable medications may lead to higher prescription rates and market expansion. Considerably, the prevalence of ED is increasing with age due to comorbid conditions such as diabetes, obesity, and others. Men with medication, hormonal, neurological, and vascular etiologies are also at a high-risk development of disease.
A lifetime ED episode was experienced by around 35 -75% of male diabetic patients, according to the WHO. By 2021, there were 422 million diabetic patients living in low- and middle-income nations. However, the market growth could be hampered by a lack of healthcare infrastructure and manufacturing mistakes. For instance, Sun Pharmaceutical Industries Ltd. announced the recall of its generic drug Tadalafil in November 2021 as a result of a production fault. This recall could leave a small gap in the supply of ED generic drugs used to treat erectile dysfunction patients.
The viagra segment held the highest revenue share of 57.8% in 2021. At present, many companies are undertaking various strategic initiatives such as research collaboration, partnerships, and agreements with an aim to expand their business footprint. For instance, in January 2020, Pfizer, Inc., and Digital Men’s Clinic Roman signed a supply agreement to provide a generic version of Viagra to roman members. This supply agreement is expected to boost the growth of the segment.
The others segment is also expected to witness lucrative market growth over the forecast period owing to the large application base and availability of ED medicines, such as Helleva (lodenafil carbonate), Mvix (mirodenafil), and others that are also used to treat adult patients with erectile dysfunction. Increasing approval of over-the-counter ED products offers easy access to ED patients. For instance, in February 2022, Adamed was the first-ever polish company that received marketing authorization approval for Tadalafil MAXON from prescription to over-the-counter (OTC) category. Hence, the introduction of such products in the market may boost the utilization of ED drugs.
North America dominated the erectile dysfunction drugs market and accounted for a revenue share of 51.7% in 2021 due to the high burden of disease, strong healthcare infrastructure, and approval of new products for treatment. In March 2022, Lupin received the U.S. FDA approval for its ANDA for sildenafil (10 mg/mL oral suspension) to market a generic equivalent to Revatio of Viatris Specialty LLC. The accessibility of affordable generic products may increase patient compliance, consequently, increasing the consumer base and revenue for the market.
In Asia Pacific, the market for erectile dysfunction drugs is expected to witness fast growth during the forecast period. The growth of the region is attributable to the entry of new products into the region. For instance, in May 2020, iX Biopharma announced the supply of Wafesil and Silcap through telemedicine in Australia for the treatment of an adult patient with erectile dysfunction.
Major players are adopting strategies such as mergers and acquisitions for regional expansion for a greater market share. For instance, the Spanish specialty pharmaceutical company Laboratorios Rubio S.A. sold the Rx brand Bandol to Aspargo Laboratories, Inc. in May 2022. Patients with ED disorders are treated with Bandol. Some of the prominent players in the erectile dysfunction drugs market include:
Pfizer Inc.
Eli Lilly and Company
Teva Pharmaceutical Industries Ltd
Sanofi
Sun Pharmaceutical Industries Ltd
Bayer AG
Petros Pharmaceuticals, Inc.
VIVUS, Inc.
Auxilium Pharmaceuticals, Inc.
Adamed
Report Attribute |
Details |
Market size value in 2022 |
USD 2.46 billion |
Revenue forecast in 2030 |
USD 4.8 billion |
Growth rate |
CAGR of 8.5% from 2022 to 2030 |
Base year for estimation |
2021 |
Historical data |
2018 - 2020 |
Forecast period |
2022 - 2030 |
Quantitative units |
Revenue in USD million and CAGR from 2022 to 2030 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Product, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
Country scope |
U.S.; Canada; U.K.; Germany; France; Spain; Italy; China; Japan; India; Australia; South Korea; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE |
Key companies profiled |
Pfizer, Inc.; Eli Lilly and Company; Teva Pharmaceutical Industries Ltd; Sanofi; Sun Pharmaceutical Industries Ltd; Bayer AG; Petros Pharmaceuticals, Inc., VIVUS, Inc.; Auxilium Pharmaceuticals, Inc., Adamed |
Customization scope |
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional, and segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-markets from 2018 to 2030. For this study, Grand View Research has segmented the global erectile dysfunction drugs market report based on product and region:
Product Outlook (Revenue, USD Million; 2018 - 2030)
Viagra
Cialis
Zydena
Levitra
Stendra
Others
Regional Outlook (Revenue, USD Million; 2018 - 2030)
North America
U.S.
Canada
Europe
Germany
U.K.
France
Italy
Spain
Asia Pacific
Japan
China
India
Australia
South Korea
Latin America
Brazil
Mexico
Argentina
MEA
South Africa
Saudi Arabia
UAE
b. The global erectile dysfunction drugs market size was estimated at USD 2,296.01 million in 2021 and is expected to reach USD 2.46 billion in 2022.
b. The global erectile dysfunction drugs market is expected to witness a compound annual growth rate of 8.5% from 2021 to 2030 to reach USD 4.8 billion in 2030.
b. Based on products, the viagra segment held the largest share of 57.9% in 2021, owing to the increasing focus of various companies on commercializing generic products in order to expand their product portfolio
b. Some key players operating in the erectile dysfunction drugs market include Pfizer, Inc.; Eli Lilly and Company; Teva Pharmaceutical Industries Ltd; Sanofi; Sun Pharmaceutical Industries Ltd; Bayer AG; Petros Pharmaceuticals, Inc., VIVUS, Inc., Auxilium Pharmaceuticals, Inc., and Adamed among others
b. Key factors driving the erectile dysfunction drugs market growth include increasing disease burden of ED, increasing product approval & launches, and supportive reimbursement policies.
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
ISO Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."
We value your investment and offer free customization with every report to fulfil your exact research needs.